Safety Study Evaluating the Adrenal Suppression Potential of Product 0405 in Pediatric Subjects With Atopic Dermatitis

Completed · Phase 2

Conditions studied: Atopic Dermatitis

In brief

The aim of the trial is to assess Adrenal Suppression potential when pediatric subjects are administered Product 0405 for the treatment of Atopic Dermatitis

Key facts

Study ID

NCT01232543

Run by

Fougera Pharmaceuticals Inc.

People needed

114

Starts

2010-11-01

Expected to finish

2011-11-01

Last updated by the study team

2012-04-11

Who can join

Age: 0 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Atopic Dermatitis
• Good health with the exception of Atopic Dermatitis
• Percent body surface area minimum requirements

You may not qualify if…

• Subjects who are pregnant, nursing, or planning a pregnancy

Where it is running

• Fougera Pharmaceuticals Inc. — Melville, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.